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IRM DE PERFUSION ET DE DIFFUSION DE LA PROGRESSION DU 
GLIOBLASTOME DANS UN ESSAI CLINIQUE PROSPECTIF DE 
4 ANS DU TEMOZOLOMIDE 
RESUME 
BUT 
Cette étude a été menée sur le suivi de patients traités pour un glioblastome nouvellement 
diagnostiqué. Son objectif a été de déterminer l'impact des séquences de perfusion et de 
diffusion en imagerie par résonance magnétique (IRM). Un intérêt particulier a été porté au 
potentiel de ces nouvelles techniques d'imagerie dans l'anticipation de la progression de la 
maladie. En effet, l'intervalle de temps libre de progression est une mesure alternative de 
pronostic fréquemment utilisée. 
MATERlEL ET METHODE 
L'étude a porté sur 41 patients participant à un essai clinique de phase II de traitement par 
temozolomide. Leur suivi radiologique a comporté un examen IRM dans les 21 à 28 jours 
après radiochimiothérapie et tous les 2 mois par la suite. L'évaluation des images s'est faite 
sur la base de l'évaluation de l'effet de masse ainsi que de la mesure de la taille de la lésion 
sur les images suivantes : Tl avec produit de contraste, T2, diffusion, perfusion. Afin de 
déterminer la date de progression de la maladie, les critères classiques de variation de taille 
adjoints aux critères cliniques habituels ont été utilisés. 
RESULAT 
311 examens IRM ont été revus. Au moment de la progression (32 patients), une régression 
multivariée selon Cox a permis de déterminer deux paramètres de survie : diamètre maximal 
en Tl (p>0.02) et variation de taille en T2 (p<0.05). L'impact de la perfusion et de la 
diffusion n'a pas été démontré de manière statistiquement significative. 
CONCLUSION 
Les techniques de perfusion et de diffusion ne peuvent pas être utilisées pour anticiper la 
progression tumorale. Alors que la prise de décision au niveau thérapeutique est critique au 
moment de la progression de la maladie, l'IRM classique en Tl et en T2 reste la méthode 
d'imagerie de choix. De manière plus spécifique, une prise de contraste en Tl supérieure à 
3 cm dans son plus grand diamètre associée à un hypersignal T2 en augmentation forment un 
marqueur de mauvais pronostic. 
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Purpose: This study was performed to determine the impact of perfusion and diffusion magnetic resonance 
imaging (MRI) sequences on patients during treatment of newly diagnosed glioblastoma. Special emphasis has 
been given to these imaging technologies as tools to potentially anticipate disease progression, as progression-free 
survival is frequently used as a surrogate endpoint. 
Methods and Materials: Forty-one patients from a phase Il temolozomide clinicat trial were included. During 
follow-up, images were integrated 21 to 28 days after radiochemotherapy and every 2 months thereafter. 
Assessment of scans included measurement of size of lesion on Tl contrast-enhanced, T2, diffusion, and perfusion 
images, as well as mass effect. Classical criteria on tumor size variation and clinicat parameters were used to set 
disease progression date. 
Results: A total of 311 MRI examinations were reviewed. At disease progression (32 patients), a multivariate Cox 
regression determined 2 significant survival parameters: Tl largest diameter (p < 0.02) and T2 size variation 
(p < 0.05), whereas perfusion and diffusion were not significant. 
Conclusion: Perfusion and diffusion techniques cannot be used to anticipate tumor progression. Decision making 
at disease progression is critical, and classical Tl and T2 imaging remain the gold standard. Specifically, a Tl 
contrast enhancement over 3 cm in largest diameter together with an increased T2 hypersignal is a marker of 
inferior prognosis. © 2005 Elsevier Inc. · 
Magnetic resonance imaging, Perfusion, Diffusion, Glioblastoma, Progression. 
INTRODUCTION 
Glioblastoma (GBM) is the most frequent primary brain 
tumor among adults (1, 2). Despite surge1y, radiotherapy, 
and adjuvant chemotherapy (3, 4), this tumor almost invari-
ably recurs at its initial site. Disease progression usually 
occurs within 3 to 6 months and rapidly leads to death. New 
treatments for patients with this malignant neoplasm have 
recently been developed. Among these treatments, temozo-
lomide, an alkylating agent, has shown activity against 
GBM (5-8). In the phase II trial on which this study is 
based, we have shown the feasibility and promising survival 
of the administration of temozolomide chemotherapy with 
concomitant radiotherapy followed by up to 6 cycles of 
adjuvant treatment (8). This approach has recently been 
shown to improve progression-free and overall survival in a 
randomized phase III trial (9). 
In parallel to the recent use of temozolomide, several 
advanced imaging technologies have become more readily 
available in cancer centers and hospitals. Thus, the frequent 
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talier Universitaire Vaudois, Bugnon 21, 1005 Lausanne, Swit-
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use of magnetic resonance imaging (MRI) has set standards 
in the brain imaging of tumors by allowing better topo-
graphie diagnosis and delineation of tumor extension. Tl 
gadolinium-enhanced imaging is used to assess the leakage 
of contrast agent through the blood-brain barrier, com-
monly disrupted in high-grade glioma, and T2-weighted 
imaging is used to estimate edema development. However, 
because of the inherent difficulty in measuring response to 
treatment or assessing true disease progression in the brain 
(10), complementary imaging techniques may be of great 
clinical significance. MRI diffusion and perfusion imag-
ing-in contrast to more complex and expensive techniques 
such as PET with amino acid tracers and thallium 201 
SPECT-can be used to supplement routine MRI investi-
gations without excessive time and cost increase (11, 12). 
Furthermore, both diffusion and perfusion imaging tech-
niques can be helpful and potentially superior to Tl and T2 
in the management of tumor evolution. For example, diffu-
sion imaging reflects cellularity (13, 14), and perfusion 
imaging may give information on vascular density and 
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angiogenesis (15-17). These advanced MRI techniques may 
improve radiologie prediction of response or progression 
and thus be helpful for the accurate treatment adjustment for 
an individual patient. 
In this study, we aimed to evaluate and confirm the added 
value of perfusion and diffusion MRI sequences in patients 
treated at a single institution within a prospective clinical 
trial. Thus, evolution of GBM in a homogeneous patient 
population was carefully monitored by a close medical and 
radiologie follow-up, with classical Tl-weighted and T2-
weighted MRI, as well as diffusion and perfusion imaging. 
This study analyzes in particular the behavior of T2, perfu-
sion, and diffusion at disease progression. Special attention 
has been given to the use of these imaging technologies as 
tools to potentially anticipate disease progression. Further·· 
more, multivariate survival analysis has been carried out to 
establish which radiologie criteria could be especially useful 
for neuroradiologists and oncologists who examine MRis of 
patients with glioblastoma. 
METHODS AND MATERIALS 
Patients and therapy 
Patients with newly diagnosed and histologically confirmed 
glioblastoma were enrolled in a prospective phase II clinical trial. 
Treatment after biopsy or surgery consisted of radiotherapy and 
concomitant temozolomide during 6 weeks, followed after a 4 
week interval by up to 6 monthly cycles of adjuvant temozolomide 
(8). Among the 64 patients enrolled in this trial, 41 patients treated 
at a single institution and for whom MRI documentation was 
available were considered for this radiologie ancillary study. Thir-
ty-five patients (85%) received at least 1 cycle of adjuvant therapy, 
and 19 patients (46%) received all 6 cycles of adjuvant temozo-
lomide. Twenty-three patients (56%) were male and 26 patients 
(63%) were at least 50 years of age. Concomitant medication and, 
in particular, corticosteroid and antiepileptie drugs were carefully 
recorded. 
Imaging and follow-up 
Baseline tumor imaging with MRI and CT was peiformed in our 
institution and in outside hospitals, and follow-up MRis were 
pe1formed solely in our institution. Thus, adequate MRI baseline 
tumor imaging was available for 28 patients. Subsequently, fol-
low-up included MRI 21 to 28 days after the end of radiochemo-
therapy and every 2 months thereafter, until disease progression. 
Progression was usually confirmed with a second MRI after an 
interval of 4 to 8 weeks but without histologie confirmation. 
Second surge1y for recurrence was usually not recommended. MR 
examinations were elaborated at 1.5 Tesla. Tl-weighted sagittal 
and T2-weighted transverse spin-echo images were obtained first. 
Diffusion-weighted images were acquired by application of a 
spin-echo echoplanar technique in which a diffusion weighted b 
factor of 1,000 s/mm2 in 3 orthogonal directions was used that 
allowed the computation of trace diffusion-weighted images. 
Twenty 5-mm thick slices with an interslice gap of 1.5 mm were 
used to cover the entire brain. Perfusion data were achieved with 
a gradient-echo echoplanar technique that allowed the acquisition 
of 10 5-mm thick slices (gap 1.5 mm) in the transverse orientation 
centered on the lesion. One stack of images was acquired every 1.2 
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seconds during the first pass of a bolus of contrast agent injected 
in an antecubital vein through a power injector (0.1 mmol/kg at a 
rate of 4 mL/s, followed by the injection of 20 mL of saline water 
at the same injection rate). Postcontrast Tl-weighted images in the 
sagittal and transverse orientation were then obtained. 
Pe1fusion series were processed on commercially available soft-
ware (Functool; General Electric Medical Systems, Milwaukee, 
WI). Two different color-coded pe1fusion maps were produced. 
The first map was based on the maximum slope of decrease of the 
MR signal during the first pass of the contrast agent through the 
brain. The second map displayed the negative-enhancement inte-
gral of the MR signal along time during this same first pass. These 
2 maps measure the cerebral blood fiow (CBF) and the cerebral 
blood volume (CBV), respectively. 
All imaging was acquired over a 40-month period between April 
1998 and August 2001. Survival data have been considered up to 
March 2002, with a median number of MRI examinations per 
patient of 6 (range, 1-21) and a median follow-up of 15.2 months 
(range, 5.3-46.5 months). 
Image review process 
Complete MRI records of each patient from study ently until 
death or until the cutoff date (August 2001) were prepared for a 
second reading. Two neuroradiologists who were unaware of the 
patients' outcome reviewed and scored the images in agreement. 
Six categories of radiologie criteria have been scored: localiza-
tion (lobe and hemisphere), mass effect, Tl contrast enhancement, 
T2 hypersignal, diffusion hypersignal, and perfusion hypersignal. 
Mass effect was reported as none, local, moderate midline shift, or 
severe midline shift. Tl contrast enhancement was described as 
absent, linear, nodular, or multiple nodular. T2 hypersignal was 
assigned a morphologie code: none, limited to a lobe, extension to 
more than a lobe, or conti·alateral extension. Signs of leucoen-
cephalopathy (diffuse T2 hypersignals that span the white matter, 
accompanied by shrinkage of overall brain volume) were also 
recorded. On diffusion-weighted images, the presence or absence 
of hypersignal was assessed, and perfusion hypersignal was graded 
on maximum slope of decrease and negative integral enhancement 
maps. 
The images were compared with the previous examination and 
variations of each criterion graded as increased, stable, or de-
creased. Tl contrast enhancement sizes were measured in milli-
meters, by use of largest diameter and orthogonal diameter (18). 
T2, diffusion, and perfusion hypersignals were measured in the 
same way. Mass-effect variation was graded according to the 
evolution of 3 classieal criteria: sulcus and cisterns vanishing, 
ventricles shift and deformation, and median line shift. 
Disease progression 
Disease progression was assessed by the tumor size variation on 
Tl contrast enhancement and clinieal parameters according to the 
Macdonald criteria (19). An increase greater than or equal to 25% 
in size, an increase in corticosteroid consumption, or a deteriorat-
ing neurologie fonction was defined as disease progression. 
Time reference 
For the purpose of this paper, the images acquired at the time of 
, disease progression are designated t0 , a reference in time used to 
monitor the disease's evolution. The behavior of T2, mass effect, 
pe1fusion, and diffusion imaging at ta. but also at the previous (L 1) 
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Table 2. Variation of radiological parameters at different follow-up times 
Follow-up time 
Parameter Variation L1 to t+l 
Tl contrast enhancement Increase 0% 100% (Il= 32) 57% (11 = 12) 
Stable 64% (Il= 16) 0% 33% (11 = 7) 
Decrease 36% (Il= 9) 0% 10% (Il= 2) 
T2 hypersignal Increase 16% (Il= 4) 63% (Il= 20) 64% (n = 14) 
Stable 68% (Il= 17) 28% (11 = 9) 32% (n = 7) 
Decrease 16% (Il = 4) 9% (Il= 3) 4% (Il= 1) 
Mass effect Increase 0% 37.5% (n = 12) 45.5% (Il = 10) 
Stable 76% (11 = 19) 50% (11 = 16) 45.5% (Il = 10) 
Decrease 24% (12 = 6) 12.5% (Il= 4) 9% (Il= 2) 
Perfusion Increase 0% 40% (Il= 8) 25% (Il= 4) 
Stable 66% (12 = 10) 55% (12 = 11) 69% (Il= 11) 
Decrease 33% (11 = 5) 5% (Il= 1) 6% (Il= 1) 
Diffusion Increase 0% 54% (Il= 13) 39% (Il= 7) 
Stable 69% (Il= 11) 42% (Il= 10) 50% (Il= 9) 
Decrease 31 % (Il= 5) 4% (Il= 1) 11% (n = 2) 
Follow-up time t0 is the first examination graded as disease progression; L 1 and t+ 1 examinations 
following ta. The percent sign (%) indicates percent of the available examinations. The value of n 
is the number of available examinations; n at L 1 is smaller than n at t0 because an examination 
before L 1 is not always available to evaluate the variation at L 1 • 
and showed an alteration caused by the tumor. By contrast, 
9 patients in this cohort showed leucoencephalopathy signs 
( overall brain volume shrinkage accompanied by a hyper-
intense T2 signal that spanned the white matter). These 
patients had a median survival time of 26.7 months (95% 
CI, 6.9 to 46.5 months). Leucoencephalopathy is a known 
late complication in patients treated for malignant glioma 
and occurs 18 to 24 months after radiotherapy. Table 1 
offers a summary of the findings and scores at postoperative 
baseline and at disease progression. 
Signs of disease progression 
The first examination with disease progression (ta) was 
monitored in comparison with its preceding (L 1) and fol-
lowing (t+ 1) examinations. Five main radiologie parameters 
were monitored: Tl contrast enhancement, T2 hypersignal, 
mass effect, perfusion hypersignal, and diffusion hypersig-
nals. At fa, all patients demonstrated an increase in T 1 
contrast enhancement. At examination L 1, no parameter 
presented a clear variation that predicted this progression. 
Specifically, no perfusion and diffusion image could antic-
ipate disease progression. Both perfusion postprocessing 
methods on cerebral blood flow (CBF) and cerebral blood 
volume (CBV) led to the same conclusion in 203 out of 220 
examinations. 
Of the other parameters, only T2 hypersignal showed a 
clear tendency to increase at ta, which thus suggests disease 
progression. On an MRI performed 2 months after first 
progression (t+ 1), the delayed tendency of the parameters to 
increase was confirmed. (Table 2, Fig. 1). 
Warning signs at disease progression 
At ta, univariate log-rank analysis was completed to iden-
tify potential prognostic factors for a multivariate model. 
Bach radiologie parameter and the clinical prognostic fac-
tors age, performance status, and debulking surgery (8) have 
been analyzed for survival. Size of Tl contrast enhance-
ment, variation of T2 hypersignal and of mass effect, de-
bulking surgery, and age were retained in this order for the 
multivariate model (Table 3). 
The multivariate analysis used a Cox model. It was per-
formed in an ascending manner; that is by addition of 1 
parameter from Table 3 at a time. Only 2 parameters, 
namely, largest diameter of Tl contrast enhancement and 
variation in T2 hypersignal, remained statistically signifi-
cant in the analysis (p < 0.05) (Table 4). Because this 
tOO"k 
90"/u 
80% 
70% 
40% 
10% 
0% 
t·I tO t+t 
Fig. 1. Potential markers of disease progression increase from first 
follow-up exarnination to time L 1, t0 , or t+ 1.White indicates perfu-
sion hypersignal. Light gray indicates diffusion hypersignal. Gray 
indicates mass effect. Dark gray indicates T2 hypersignal. Black 
indicates Tl contrast enhancement. Values are displayed in percent of 
the examinations available, as an examination before L 1 is not always 
. available to evaluate the variation at L 1• Abbreviations: ta, first 
examination graded as disease progression; L" t+" examination 
preceding and following, respectively, after t0 . 
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Table 3. Univariate log-rank survival analysis 
Grouping parameter* p Value at t0 
T 1 largest diameter 
23 cm <0.001 (11 = 16 vs. 16) 
<3cm 
T2 hypersignal 
Increase <0.005 (11 = 21 vs. 11) 
No increase 
Mass effect 
Increase <0.02 (11 = 12 vs. 20) 
No increase 
Debulking surgery 
Full or partial <0.02 (Il = 25 vs. 7) 
None 
Age at diagnostic 
250 y <0.05 (Il = 21 vs. 11) 
<50 y 
Median survival in 
months (95% CI) 
13.6 (6.3-20.9) 
26.8 (14.6-39.0) 
14.3 (10.4-18.2) 
42.7 (30.7-54.7) 
8.8 (5.3-12.3) 
17.l (6.5-27.7) 
16.7 (16.1-17.3) 
10.6 (3.0-18.2) 
12.l (5.2-19.0) 
26.8 (10.7-42.9) 
Median progression-free 
survival in months (95% CI) 
6.1 (4.3-7.9) 
8.7 (0-20.7) 
6.3 (5.7-6.9) 
18.2 (0-39.6) 
6.3 (5.7-6.9) 
18.2 (0-39.6) 
8.7 (8.5-8.9) 
5.5 (4.3-6.7) 
6.1 (5.3-6.9) 
13.7 (7.4-20.0) 
Follow-up time t0 is the first examination graded as disease progression. 
* Each grouping parameter splits the patients in two subsets. Survival of the first subset was tested against the survival of the second 
subsèt. The two values of /1 are the number of patients in each two subsets. 
analysis identified only 2 parameters as.significant, an over-
all score at disease progression could not be proposed. 
However, at first progression (t0), the subset of 14 patients 
with a Tl contrast enhancement largest diameter above 3 
cm in size and simultaneously a T2 hypersignal that in-
creased since last examination (L 1) had a median survival 
of 13.6 months (95% CI, 5.8 to 21.4 months) compared with 
a median survival of 28.2 months (95% CI, 10.8 to 45.6 
months) for the other 18 patients. This difference in survival 
time was significant (log-rank p < 0.001), which demon-
strated that these 2 parameters are crucial radiologie warn-
ing signs at progression. 
DISCUSSION 
Over the past 10 years, MRI has become the principal 
imaging modality on which clinicians base the follow-up 
and the evaluation of brain tumors. MRI and assessment of 
clinical parameters such as neurologie fonction and corti-
costeroid use are integral parts of the widely used Mac-
donald' s response criteria for primary brain tumors (19). 
However, some specific aspects of the follow-up, such as 
response assessment and tumor-specific imaging, increas-
ingly challenge radiologists (22). Delayed morphologie 
changes caused by treatment and contrast uptake on blood-
brain barrier disruption after surgery or radiotherapy are 
difficulties that may obscure the picture. For these reasons, 
additional imaging techniques may be of help (22). In specific 
situations, positron emission tomography (PET) that use amino 
acids tracers and 201 TI single-photon emission computed to-
mography (SPECT) have demonstrated additional value for 
the imaging of brain tumors (11, 12). These techniques are 
nonetheless far from being commonly available in health 
centers, and performing an additional examination is a bur-
den to the patients and the health-care system. 
Recent works have shown the potential of perfusion and 
diffusion imaging in assessment of tumor development. 
Histologie changes such as angiogenesis are evaluated by 
perfusion and cellularity is evaluated by diffusion imaging 
(13, 15-17). We assessed in a group of 41 homogeneously 
treated patients with glioblastoma (GBM) whether these 
techniques would allow us to anticipate disease progression. 
In particular, for the evaluation of new treatment or new 
chemotherapy agents, progression-free survival is fre-
quently used as a surrogate endpoint (23). To our knowl-
edge, few reports on gliomas specifically focus on Grade IV 
astrocytoma, and none includes a homogeneous set of pa-
tients comparable with ours. In our study, despite careful, 
Table 4. Multivariate Cox mode! (proportional hazards) of survival 
Follow-up time 
ta t+l 
Parameter p Value Hazard ratio 95% CI p Value Hazard ratio 95% CI 
Tl largest diameter <0.02 5.7 1.5-22 <0.05 3.9 1.0-15 
T2 hypersignal <0.05 3.0 l.<Y--8.9 <0.05 5.7 1.0-31 
Follow-up time t0 is the first exarnination graded as disease progression; t+ 1 exarnination follows t0 . 
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onsistent, and frequent (every 2 months) evaluation, we 
buld not show that perfusion and diffusion techniques 
1
dded valuable information. These 2 techniques did not 
1nticipate disease progression. 
! Other reports in animal models are consistent with the 
.esults of our clinical trial. In effect, on GL261 implanted 
)1ouse gliomas, T 1 contrast enhancement has been shown to 
pe present before evidence of angiogenesis (17). Thus, 
plood- brain barrier disruption is not necessarily caused by 
~eovascularization. Furthermore, for GBM in humans, per-
fusion is not positively correlated with tumor growth. Pos-
sibly, the microvasculature of such hypercellular glioma 
bannot meet the metabolic demands of the growing tumor. 
fschemic necrosis is then the logical outcome of this pecu-
)iar unstable state (16). 
The value of the diffusion technique is subject to much 
.debate. Diffusion hypersignal on diffusion-weighted trace 
limages increases with cellularity (14), whereas it decreases 
lduring edema development (24). A consequence of this 
/condition is a rather complex behavior in tumors in which 
iboth increased cellularity and increased edema are present. 
ilndeed, as the tUmor grows and its cellularity tends to 
· increase, disruption of the blood-brain. barrier will lead to 
edema. These factors then have radiologie effects on diffu-
sion behavior that tend to counteract each other. A recent 
study on patients with various brain tumors and treatments 
has shown the potential of diffusion variation to delineate 
tumor regions that respond to treatment at a very early 
timepoint during radiation therapy (25). Compared with that 
study, our work focuses on diffusion variation in relation 
with disease progression at a longer time scale in a homo-
geneous population of GBM. In this setting, diffusion vari-
ation was not able to anticipate disease progression. In a 
similar way, the 8 patients with progressive disease of the 
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Moffat et al. (25) study presented only minor changes in 
ADC. Indeed, because diffusion imaging reflects his-
topathological changes, further studies should focus on ho-
mogenous populations in terms of pathology and treatment. 
For example, lower-grade gliomas show different his-
topathological patterns that will lead to other imaging ef-
fects, whereas nonenhancing malignancies would certainly 
benefit on follow-up techniques that do not rely on contrast-
enhancement techniques. 
Hence, perfusion and diffusion showed a rather complex 
behavior and did not enable us to foresee disease progres-
sion. Classical parameters, thus, remain the imaging refer-
ence. A Tl contrast enhancement of over 3 cm in largest 
diameter together with the increase of T2 hypersignal is 
proposed as a marker of inferior prognosis. Conventional 
clinical and radiologie parameters of tumor progression 
have confirmed their usefulness in our study. Moreover, our 
MRI follow-up scheme, with simple time course denomi-
nations such as t_ 1, t0 , and t+ 1 and multivariate anal y sis, bas 
demonstrated its pertinence and could easily be transposed 
to other brain tumors and treatments. When used on large 
cohorts, this statistical approach would certainly lead to the 
identification of more parameters that could then be brought 
together in useful prognostic scoring functions. 
In conclusion, our work showed that although elaborate 
imaging techniques such as perfusion and diffusion MRI are 
becoming standardized in many medical centers, they do 
not enable the radiologist to anticipate disease progression. 
Classical Tl imaging remains the gold standard in the 
follow-up of tumor growth. Together with T2 imaging, this 
technique is accurate in reflecting the current evolution of 
the brain tumor. The quest for more precise imaging tech-
niques to monitor biologie effects of treatment for high-
grade gliomas continues (22). 
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